Drug intelligence / Profile preview

Graneodin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Administration: Topical, Oromucosal, Oral

Overview

Graneodin is an established over-the-counter (OTC) consumer health product. It was part of a portfolio of brands that Bristol-Myers Squibb licensed to Reckitt Benckiser for exclusive sales, distribution, and marketing rights in Latin America, primarily Mexico and Brazil. Bristol-Myers Squibb maintained manufacturing and supply responsibilities for the product during the initial collaboration period.

Brand names: Graneodin

Beyond the preview

Go deeper on Graneodin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Graneodin.

Explore the full profile